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Abstract
This study was aimed at assessing the trend of worldwide pop-
ularity, thus likely reflecting usage, of conventional cardiac bio-
markers, including cardiac troponins, myoglobin and creatine
kinase MB (CK-MB). Google Trends was interrogated using a
combination of the three search terms “troponin” AND “myoglo-
bin” AND “CK-MB”, with a time limit set between January 1,
2014 (i.e., the oldest searchable year) and present time (i.e., August
13, 2018). The raw data were entered into an Excel worksheet and
reported as cumulative Google Trends scores per week for each
cardiac biomarker. The popularity score of myoglobin and CK-MB
has displayed a significantly decreasing trend since the 2004,
whilst that of troponin has exhibited an apparently paradoxical U-
shape behavior, with a more pronounced increase during the past
10 years. The correlation between time and cumulative Google
searches was significant for all biomarkers, being r= 0.40
(P<0.001) for troponin, r= -0.45 (P<0.001) for myoglobin and r= -
0.79 (P<0.001) for CK-MB. The score of overall Google searches
for troponin was approximately 2.5-fold and 8.5-fold higher than
for myoglobin and CK-MB, respectively. When the analysis was
limited to the past ten years, the correlation between time and
cumulative Google searches became even stronger for troponin (r=
0.85; P<0.001), remained virtually identical for CK-MB (r= -0.80;
P<0.001), whilst it was no longer significant for myoglobin (r= -
0.13; P=0.150). The graphical analysis of Google search frequency
also showed that CK-MB appears to be popular in Mexico, Brazil,
Chile, Japan, Poland and Romania, myoglobin seems popular in
Uruguay, Bolivia, Denmark, Kazakhstan and in some African
Nations, whilst troponin is mostly predominant in the remaining
parts of the world. The results of this study suggest that, despite all
available guidelines share the principle that cardiac troponin
should be considered the one and only reference biomarker for
diagnosing myocardial ischemia, CK-MB and especially myoglo-
bin are still popular worldwide, especially in certain geographic
areas.
Introduction
Although the vast majority of national and international guide-
lines,1-5 along with reiterated scientific claims,6,7 strongly discour-
age the use of biomarkers other than cardiac troponin I (cTnI) and
T (cTnT) for diagnosing acute myocardial infarction (AMI), evi-
dence persists that myoglobin and creatine kinase isoenzyme MB
(CK-MB) may be still largely available in many clinical laborato-
ries, and would be hence employed by many clinicians for diag-
nosing AMI around the world. For example, a very recently nation-
al survey showed that the use of obsolete cardiac biomarkers,
namely myoglobin and CK-MB, is still relatively frequent in Italy,
wherein the percentage of facilities still using either of these two
biomarkers in combination with cardiac troponins was found be as
high as 33% and 26%, respectively.8 Similar data were reported by
another recent US-based survey, according to which the combina-
tion of cardiac troponins with other biomarkers was as high as
50%.9
Google Trends (Google Inc. Mountain View, CA, USA) is a
freely searchable Web-based software, which displays the relative
frequency over customized time and location of how much a spe-
cific search term is interrogated in Google.10 The output of the
search is a graph, which displays on the y axis the frequency of
how one or more terms have been searched in Google, whilst the x
axis reports the period of time over which the search has been car-
ried out. The cumulative number of Google searches is then dis-
played along an arbitrary scale, ranging between 0 and 100. A
value of 100 (i.e., the peak) reflects the highest number of Google
searches for the term, a value of 50 reflects 50% the number of
Google searches compared to the peak, whilst a value <1 mirrors a
number of Google searches <1% than the peak. The use of Google
Trends has now become commonplace in a variety of clinical set-
tings, especially for analyzing epidemiologic trends of diseases
and drugs usage,10,11 so that is can now be reliably applied also in
the field of laboratory medicine, for assessing how much certain
biomarkers are searched in Google and, thereby, how much they
are popular and used in routine clinical practice.
Therefore, we carried out an original study based on a Google
Trends analysis, aimed at assessing the trend of worldwide popu-
larity of conventional cardiac biomarkers including troponin, myo-
globin and CK-MB.
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Materials and Methods
Google Trends was interrogated using a combination of the
three search terms “troponin” AND “myoglobin” AND “CK-MB”,
with a time limit set between January 1, 2014 (i.e., the oldest
searchable year) and present time (i.e., August 13, 2018).
According to the Google Trends algorithm, search results were
rated according to the peak of popularity (i.e., a value of 100)
recorded throughout the search period. The raw data were then
entered into an Excel worksheet and reported as cumulative
Google Trends scores per week. The statistical analysis was based
on Spearman’s correlation (including 95% confidence interval;
95% CI), using Analyse-it (Analyse-it Software Ltd, Leeds, UK).
The study was performed in accordance with the Declaration of
Helsinki and under the terms of all relevant local legislations.
Results
The output of the Google Trend search using the keywords
“troponin”, “myoglobin” and “CK-MB” is shown in Figure 1. The
popularity score of myoglobin and CK-MB displayed a clear
decreasing trend over time, whilst that of troponin exhibited an
apparently paradoxical behavior, resembling a typical U-shape
relationship, with a more pronounced increase of Google Trends
score during the past 10 years. The Spearman’s correlation
between time and cumulative Google searches was significant for
all biomarkers, being r= 0.40 (95% CI, 0.26 to 0.51; P<0.001) for
troponin, r = -0.45 (95% CI, -0.56 to -0.33; P<0.001) for myoglo-
bin, and r = -0.79 (95% CI, -0.84 to -0.73; P<0.001) for CK-MB.
Throughout the search period, the score of overall Google searches
for troponin (i.e., 11430; 66.9% of all Google searches) was
approximately 2.5-fold and 8.5-fold higher than for myoglobin
(i.e., 4306; 25.2% of all Google searches) and CK-MB (i.e., 1355;
7.9% of all Google searches), respectively. Even more interesting-
ly, when the Google Trends score of each biomarker was reported
as percentage of all Google searches for the three biomarkers, a
much more consistent trend was observed, with Spearman’s corre-
lation between time and Google searches being r= 0.80 (95% CI,
0.75 to 0.85; P<0.001) for troponin, r= -0.67 (95% CI, -0.75 to -
0.58; P<0.001) for myoglobin and r= -0.73 (95% CI, -0.79 to -
0.65; P<0.001) for CK-MB, respectively (Figure 2).
When the analysis was limited to the past ten years (i.e.,
between August 2008 and August 2018), the correlation between
time and cumulative Google searches became even stronger for
troponin (r = 0.85, 95% CI 0.80 to 0.90; P<0.001), remained virtu-
ally identical for CK-MB (r = -0.80, 95% CI, -0.86 to -0.73;
P<0.001), whilst it was no longer significant for myoglobin (r = -
0.13; 95% CI, -0.30 to 0.05; P=0.150). Over this 10-year period,
the score of Google searches for troponin (i.e., 7953; 69.4% of all
Google searches) further increased to approximately 3.0-fold and
9.7-fold that of myoglobin (i.e., 2689; 23.5% of all Google search-
es) and CK-MB (i.e., 816; 7.1% of all Google searches), respec-
tively.
A graphical analysis of Google search frequency according to
worldwide geography is shown in Figure 3. Interestingly, CK-MB
appears to be popular in Mexico, in some Latin American countries
(e.g., Brazil and Chile), Japan, Poland and Romania, myoglobin
seems popular in some other Latin American countries (e.g.,
Uruguay and Bolivia), Denmark, Kazakhstan and in some African
Nations, whilst troponin is mostly predominant in the remaining
parts of the world.
Discussion and Conclusions
Although a large number of AMI guidelines and recommenda-
tions have become available at both international and national
level, all of which sharing the same straightforward principle that
cardiac troponin (either cTnT or cTnI) should be considered the
                                                                                                                              Article
Figure 1. Chronological evolution of cumulative worldwide
Google Trends score for the keywords “troponin”, “myoglobin”
and “CK-MB”. CK-MB, creatine kinase isoenzyme MB.
Figure 2. Chronological evolution of percentage worldwide
Google Trends score for the keywords “troponin”, “myoglobin”
and “CK-MB”.
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one and only reference biomarker for diagnosing myocardial
ischemia,12 evidence remains that additional tests, namely myoglo-
bin and CK-MB, may still be used for diagnosing AMI in many
healthcare facilities.
The results of our analysis, based on Google Trends, clearly
reflects this perception. In agreement with two recent nationwide
surveys,8,9 we hence showed that despite the popularity of myoglo-
bin and CK-MB has substantially declined over time, nearly one-
third of cumulative Google searches still regarded these two bio-
markers. Since it has been convincingly demonstrated that Google
Trends is a reliable tool for complementing traditional collection
and analysis of data used for many healthcare applications, includ-
ing disease epidemiology, diagnosis and therapy,13-15 the findings
of our analysis would hence suggest that CK-MB, and especially
myoglobin, are still broadly searched (and thereby probably used)
biomarkers, especially in certain geographic areas, as those shown
in Figure 3. Indeed, the popularity of CK-MB has constantly
declined over time, exhibiting a nearly 50% decline throughout our
observational period (i.e., between the years 2004-2018), which
was mostly pronounced in the last 10 years. Conversely, the popu-
larity of myoglobin has displayed a consistent decline between 15-
10 years ago, but has then remained fairly stable during the past 10
years (Figure 1). Notably, the popularity trend of cardiac troponin
has exibited a quite paradoxical behavior, reaching its nadir
between the years 2004 and 2008, but then constantly growing dur-
ing the past 10 years (Figure 1). This constantly incremental trend
is more clearly perceptible when Google Trends score is reported
in percentage of all Google searches (Figure 2) and has virtually
coincided with, and then paralleled, the development and commer-
cialization of a new generation of high-sensitive cardiac troponins
immunoassays,16,17 which have virtually revolutionized the diag-
nostic approach to patients with suspected AMI, leading to an irre-
versible obsolescence of whatever else putative cardiac biomarker.
These findings are essentially aligned with those presented in other
earlier surveys, showing that the so-called obsolete cardiac bio-
markers (i.e., myoglobin and CK-MB) are still widely available
worldwide, with a frequency of usage that has been reported to be
as high as 50%.8,9
Some hypotheses can be made for justifying our findings. The
first important aspect is perhaps the gap of knowledge on, or
adherence to, the most recent AMI guidelines. Several lines of evi-
dence now attest that there is a compelling need for both reinforced
education of emergency physicians and strengthened adherence to
available recommendations in emergency care settings, which
would then allow to more efficiently translating skills into clinical
practice.18,19 The diagnosis of AMI makes no exception to this rule,
as recently emphasized by Hachey et al.,9 who showed that AMI
guidelines or recommendations are only followed by less than 40%
of US physicians. This aspect has meaningful clinical implications,
as recently highlighted by Shah et al.,20 who demonstrated that
poor adherence to evidence-based management of patients with
non-ST elevation myocardial infarction is associated with 10%
higher 3-year mortality after hospital discharge. Notably, laborato-
ry professionals and cardiologists are not exempted from this edu-
cational drawback. In particular, Collinson et al. recently showed
that an important gap remains between best-practice AMI recom-
mendations and laboratory practice, with many clinical laborato-
ries still providing diagnostic panels including CK and/or CK-MB
and/or myoglobin,21 whilst Breuckmann et al. emphasized that
noncompliance with AMI guidelines is over 60% in chest pain
units, especially when managing patients with high to intermediate
risk.22
Defensive medicine is a second important driver of inappropri-
ate requests for obsolete cardiac biomarkers. The use of laboratory
resources should always be discretionary, and shall hence be guid-
ed by accurate assessment of pre-test probability according to clin-
ical history, signs and symptoms.23 However, the real practice is
often different from the theory. Many clinicians may be persuaded
that the larger is the panel of laboratory tests requested, the less
likely is the chance of missing a diagnosis,24,25 especially for med-
ical conditions with the highest number of malpractice claims,
such as AMI.26 This does not hold true, however, as recently
emphasized by Alvin et al.,7 wherein inappropriate or unjustified
prescription of obsolete cardiac biomarkers (especially CK-MB) is
associated with otherwise preventable healthcare expenditure, no
added value for patient care, but also with the risk of generating
false positive test results, which might then trigger unwarranted
and even invasive diagnostic investigations (e.g., angiography).
Regarding myoglobin, another different explanation may
coexist. Unlike CK-MB, which has been almost exclusively used
for diagnosing myocardial (prevalently ischemic) injury, myoglo-
bin is currently used for investigating patients with skeletal muscle
injuries, especially with rhabdomyolysis.27 More specifically, evi-
dence has been brought during the past 10 years that myoglobin
may predict the development of acute kidney injury much more
efficiently than any other muscular biomarker, including total
CK.28 Therefore, the Google Trends score recorded for myoglobin
may have been artificially inflated by many Google searches focal-
ized on skeletal muscle diagnostics rather than on cardiac testing.
This would also explain the lower decrease of Google searches
recorded during the last few years, which are those corresponding
to the renaissance of this biomarker for diagnosing and monitoring
skeletal muscle damage.28
We also acknowledge that this study may have some limita-
tions. First, the searches were performed using English terms, and
it is hence conceivable that the overall (but not the relative) num-
ber of hits may have been biased in some countries where English
is not the most spoken language. Notably, we carried out an addi-
tional search using either the search terms in English or Italian, but
the final trends were almost unvaried (data not shown). Then, the
search terms were entered with no reference to the aim of diagnos-
ing myocardial ischemia, since this option is not allowed in Google
Trends, and this may have hence contributed to introduce addition-
al variability in our findings. Therefore, the results of our study
                             Article
Figure 3. Geographical distribution of the Worldwide Google
Trends score for the keywords “troponin”, “myoglobin” and “CK-
MB”.
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should be regarded as an approximation of the overall popularity
of these terms, but do not implicitly reflect the direct usage of these
biomarkers.
In conclusion, the results of our study support, and even broad-
en, previous nationwide information that the worldwide AMI diag-
nostics is still partially based on obsolete or redundant biomarkers
(i.e., myoglobin and CK-MB). Specific educational efforts should
hence be planned for promoting the dissemination of currently
available AMI guidelines and for preventing unjustified test
requests only triggered by defensive medicine.
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